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Abstract 
 
Many drugs have been reported to cause thrombotic microangiopathy (TMA), yet evidence supporting a direct 
association is often weak. In particular TMA has been reported in association with recombinant type I interferon 
therapies, with recent concern regarding the use of interferon in multiple sclerosis patients. However a causal 
association has yet to be demonstrated. 
 
Here we adopt a combined clinical and experimental approach to provide evidence of a such an association between 
type I interferon and TMA. We show the clinical phenotype of cases referred to a national centre is uniformly 
consistent with a direct dose-dependent drug-induced TMA. We then show that dose-dependent microvascular 
disease is seen in a transgenic mouse model of interferon toxicity. This includes specific microvascular pathological 
changes seen in patient biopsies, and is dependent on transcriptional activation of the interferon response through the 
type I interferon receptor (IFNAR).  
 
Together our clinical and experimental findings provide evidence of a causal link between type I interferon and 
thrombotic microangiopathy. As such, recombinant type I interferon therapies should be stopped at the earliest stage 
in patients who develop this complication, with implications for risk mitigation. 
 
 
  
Key Points 
 
• Type I interferon therapies can cause a dose-dependent thrombotic microangiopathy 
 
• Recombinant type I interferon therapies should be stopped at the earliest opportunity in patients who 
develop thrombotic microangiopathy 
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Introduction 
Thrombotic microangiopathy (TMA) syndromes are characterised by endothelial dysfunction, microangiopathic 
haemolytic anaemia and microvascular ischaemia, with diverse aetiologies which include drugs1,2. Clinicians 
evaluating TMA patients must decide whether a particular drug is likely to have caused the disease. This difficult 
decision requires high quality evidence, and recent work has highlighted the difficulty of attributing a causal 
relationship1. TMA is typically a rare but serious adverse event which can occur after many years of treatment. As 
such, an association is unlikely to be detected in randomised controlled trial data3. Therefore, for the large majority of 
drugs, causality with TMA is inferred from isolated case reports, without wider analyses of drug safety data or 
experimental evidence1.  
 
This problem is exemplified by recombinant type I interferon therapies. Recombinant interferon-α and interferon-β 
therapies act through the common type I interferon receptor IFNAR, and are widely used for the treatment of 
neoplastic, autoimmune and infectious diseases4. Case reports have linked TMA to both interferon-α and interferon-β 
therapies, the main subclasses of type I interferon5,6. Particular concern has been recently raised regarding interferon-
β use in multiple sclerosis patients, where fatal cases of TMA have been observed6,7. However a causal role for 
interferon remains to be demonstrated, and alternative confounding aetiologies such as other drugs, complement 
mutations and E.coli exposure have been suggested6,8.  
 
Establishing causation in drug safety is a major challenge. Frameworks have been proposed to support evidence of a 
causal association between disease and environmental factors, the best known of which are the Bradford-Hill 
criteria9,10. Such frameworks include a potential role for biological and experimental studies in establishing causation. 
As such the demonstration of causality in drug safety benefits from a multifaceted approach to the adverse drug 
event, encompassing analyses of individual cases, drug safety data and experimental evidence10. Critically, such 
analyses require accurate description of the adverse drug event of interest. This is particularly relevant to the study of 
TMA since this is a pathophysiologically heterogeneous syndrome, with at least nine primary TMA syndromes 
described2. It is also important to establish whether an adverse event is caused by the drug’s active ingredient or by 
other drug components11 12. For example, renal failure caused by intravenous immunoglobulin therapy is associated 
with the high sucrose content of the drug, rather then the immunoglobulin itself, with important implications for 
understanding the adverse event and managing risk 11.  
 
To address these questions we performed a detailed clinical analysis of type I interferon-associated TMA cases 
presenting to a national TMA centre to identify important features of the clinical phenotype of this complication. We 
provide experimental evidence which suggests that the interferon protein itself directly causes microvascular disease, 
using a transgenic model of type I interferon (interferon-α1) toxicity. We subsequently consider the potential 
implications of these findings for the safety of patients receiving recombinant type I interferon therapies.  
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Methods 
 
Patient evaluation and drug safety data  
Patients with multiple sclerosis who developed thrombotic microangiopathy with interferon-β therapy were referred to 
the national TMA centre in Newcastle for further evaluation13. The study was approved by Newcastle and North 
Tyneside 1 Research Ethics Committee (MREC/1/3/83). Individual patient interferon dose was determined from 
patient records and adjusted for weight (mcg/kg). Dose-response was also further assessed through analysis of 
national spontaneous reporting data. Requests for safety data were submitted in the context of a registered patient 
safety audit (NHS Lothian DCNQIT417). Cases of interferon-associated thrombotic microangiopathy reported 
throughout the UK were identified through a request for spontaneous data submitted to the UK Medicines and 
Healthcare products Regulatory Authority (MHRA). All spontaneously reported cases of thrombotic microangiopathy 
associated with recombinant interferon-β from 1999 to January 2016 to the MHRA were identified, using search 
criteria “haemolytic uraemic syndrome”, “thrombotic thrombocytopenic purpura”, “thrombotic microangiopathy” and 
“malignant hypertension”. These cases represent all TMA cases spontaneously reported using the UK “Yellow Card” 
spontaneous reporting scheme as well as UK cases reported in the published literature.  
 
Immunohistochemical analysis 
Paraffin-embedded renal biopsies from patients with IFN-β-associated thrombotic microangiopathy were cut into 5 µm 
sections, rehydrated and boiled in sodium citrate buffer (pH 6.0). Sections were stained with mouse-anti-MxA (kind 
gift, Otto Haller, University of Freiburg; 1:400) followed by staining with EnVision™ G|2 System/AP Rabbit/Mouse 
(Dako) and counterstained with Mayer’s hematoxylin (Merck).  
 
In vitro effects of type I interferon on endothelial cells 
BEND.5 immortalised mouse brain endothelial cells were plated at 5 x 105 cells per well of a 6 well plate in 1 ml 
DMEM containing 10% FCS and incubated at 37°C with 5% CO2. Recombinant mouse or human IFN-  or IFN-  (R+D 
Systems: Mouse interferon alpha A, 12100-1, mouse interferon beta 12400-1, human interferon beta 1a 11415-1, 
human interferon alpha 2 11105-1) was added to culture media at concentrations 0-104U/mL and incubated for 24 
hours. Total RNA was isolated from each well using QIAshredder and RNeasy (QIAGEN), according to the 
manufacturer’s instructions. Each biological replicate was assayed for expression of Oas1A and Ifit1 and the 
housekeeping gene Hprt using Brilliant II SYBR master mix (Agilent technologies). Thermocycling and data acquisition 
were performed using ABI Prism 7900HT Real-time PCR system. A t-test was performed to compare relative gene 
expression at highest interferon dose to no interferon. (GraphPad Prism Version 6.0d). For human endothelial cells we 
accessed publically available microarray data from Interferome v 2.0114 for human endothelial cells (HUVECs) treated 
with interferon-α and interferon-β (recombinant  protein from Schering-Plough at 1000 IU/ml)15. The fold-change for 
genes in interferon-α and interferon-β treated HUVECs were compared. 
 
Analysis of microvasculature in a mouse model of type I interferon toxicity 
The generation of transgenic mice (termed GFAP-IFNα1) with astrocyte-targeted, brain-specific production of type I 
interferon has been described previously16. Animal experiments were approved by University of Sydney Animal Ethics 
Committee (protocol number 5374). All animal experimental procedures were carried out in compliance with local 
procedures and guidelines. The microvasculature of non-transgenic littermate wildtype mice (WT), transgenic mice 
with low levels of astrocyte-derived IFN-α1 production (IFN Low) and high levels of IFN-α1 production (IFN High) was 
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examined and quantified. Mice were perfused intracardially at 2-3 months of age, with ice-cold saline followed by 4% 
paraformaldehyde in PBS (n=8, each group). Brains were removed, postfixed overnight in the same fixative, 
dehydrated through graded alcohol solutions, and embedded in paraffin. For immunohistochemical detection of T cells 
and endothelial cells, sections were deparaffinized, rehydrated in graded alcohol, rinsed in phosphate-buffered saline 
(PBS), and blocked for 1 hour at room temperature in PBS containing 1% bovine serum albumin. The sections were 
then incubated overnight at 4°C with primary antibody diluted in blocking buffer (CD3, Abcam rabbit monoclonal 
ab16669 and CD31, Abcam rabbit polyclonal ab28364). The sections were then washed in PBS and incubated with 
anti-rabbit avidin-biotinylated horseradish peroxidase complex (ABC kit; Vector, Burlingame, CA) used according to 
the manufacturer’s instructions. The total number of microvascular abnormalities was counted across three X20 
magnification fields per anatomical region, with counting performed blind to mouse genotype. One-way ANOVA was 
performed across groups for each anatomical region (GraphPad Prism Version 6.0d). For rescue experiments IFNHigh 
mice were crossed to IFNAR-/- mice, which lack a functional type 1 interferon receptor17.  
 
For RNA analysis, whole brain was removed and immediately snap-frozen in liquid nitrogen. Total RNA was extracted 
from the tissue samples using TriReagent (Sigma-Aldrich) performed according to the manufacturer’s instructions. 
The RNA concentration of the samples was determined by UV spectroscopy at 260 nm. For all probe sets, a fragment 
of the L32 gene was included and served as an internal loading control. The ribonuclease protection assays (RPAs) 
for interferon response genes were performed and analyzed as described previously18,19, with autoradiographs 
quantified by densitometry using Image J software, n=3 each group.  
 
Vascular casting of interferon transgenic mice 
Vascular casting of WT (n=2) and IFNHigh mice (n=6) was performed as previously described20, in accordance with 
National Institutes of Health Guidelines for Care and Use of Laboratory Animals. Briefly, deeply anesthetized animals 
were perfused with artificial cerebrospinal fluid (ACSF) containing Heparin, followed by 4% paraformaldehyde in PBS, 
and an injection of the resin Mercox (Ladd Research, Williston, VT). After resin curing, soft tissue was subsequently 
macerated followed by decalcification with 5% formic acid. Casts were washed, then dried by lyophilization, mounted 
on stubs, and sputter-coated with gold for routine scanning electron microscopy. 
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Results  
 
Interferon-β causes a direct drug-induced thrombotic microangiopathy 
In view of the recent regulatory concerns regarding the potential association between type I interferon therapy and 
TMA in multiple sclerosis patients6, we first performed a detailed analysis of the clinical features of interferon-β 
associated thrombotic microangiopathy. The clinical phenotype of new and index6 cases of interferon-β associated 
TMA in multiple sclerosis patients was reviewed by the UK national thrombotic microangiopathy centre13 (n=8, Table 
1, Figure 1). Microangiopathic haemolytic anaemia, renal failure and severe hypertension were universally seen and 
at least one other organ was affected, with prominent brain and cardiac involvement. (Figure 1A-D). No patient 
received any other drugs associated with TMA1 and no other confounding TMA triggers or other autoimmune diseases 
were identified1,21,22,23. Detailed genetic evaluation, including exome sequencing, did not identify mutations in any 
gene associated with thrombotic microangiopathy. The final diagnostic evaluation by the national centre was uniformly 
consistent with a chronic drug-induced thrombotic microangiopathy (Table 1, Supplementary Table 1)1,24,25.  
 
Drug-induced thrombotic microangiopathies can be caused by a direct toxic effect of the drug or via indirect immune-
mediated mechanisms1. Given that direct toxic reactions are typically dose-dependent24, we next examined the 
relationship between TMA and interferon dose. Affected patients were all in the bottom weight quartile, adjusting for 
age and sex26. This observation of low weight was replicated in an independent case series7. Therefore patients who 
developed TMA received a significantly higher weight-adjusted interferon dose than those who did not develop the 
complication (Figure 1E P<0.001 t-test). To confirm this dose-dependence we requested national spontaneous 
reporting data from the UK Medicines and Healthcare Products Regulatory Agency. This showed that all cases were 
associated with a dose of interferon-β in excess of 50mcg per week, with 92% of cases associated with the highest 
available dose (Figure 1F). Evidence of interferon bioactivity (Figure 1G-H) was detected in patient renal biopsies, and 
anti-interferon antibodies were not detected in any patient, consistent with a direct rather than immune-mediated effect 
of the drug. Taken together these results suggest that interferon-β causes a toxic drug-induced thrombotic 
microangiopathy in multiple sclerosis patients.  
 
Thrombotic microangiopathy is observed with all type I interferon subtypes 
We next asked whether TMA was observed with all subtypes of recombinant type I interferon therapies in clinical use. 
The type I interferon family of proteins consists of a family of 13 alpha subtypes and a single major beta subtype27. 
These subtypes exhibit structural similarity and exert their biological activity via the common type I interferon receptor 
IFNAR (Figure 2A). Recombinant interferon-α therapies are used to treat a broad range of diseases such as CML, 
hepatitis C and melanoma. Systematic review of the literature shows that thrombotic microangiopathy has been 
reported as a complication of every subtype of recombinant type I interferon in clinical use; IFNα2a, IFNα2b, IFNβ1a 
and IFNβ1b (Figure 2B, Supplementary Figure 1).  
 
We next compared the detailed clinical phenotype described here of interferon-β associated TMA with a comparably 
detailed analysis of a series of interferon-α associated TMA, analysed at a specialised centre5 (n=8 both groups). A 
similar clinical phenotype is observed in both case series (Supplementary Table 2). Specifically, interferon-α and 
interferon-β TMA were associated with long-term therapy at high-doses5. Both groups displayed severe hypertension, 
predominant involvement of the renal microvasculature, moderate thrombocytopenia and a poor renal outcome. All 
published cases are summarised in the supplementary tables 3 and 4 and confirm that this clinical picture is seen in 
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the majority of patients. Furthermore, the transcriptomic response of human endothelial cells to both human 
interferon-α and interferon-β are highly correlated (Figure 2C, r=0.97)15. Therefore thrombotic microangiopathy can 
occur with all subtypes of recombinant type I interferon therapies, and these subtypes exert an almost identical effect 
on endothelial cells.  
 
Thrombotic microangiopathy is associated with “interferonopathic” disease 
An activated type I interferon response can be induced by recombinant protein therapies, but can also occur 
spontaneously in patients in whom endogenous levels of type I interferon are pathologically elevated. These 
“interferonopathic” diseases include monogenic disorders of interferon dysregulation, as well as more common 
autoimmune diseases such as SLE28,29. We reviewed pathological findings from patients with different diseases where 
transcriptomic evidence of an interferon signature has been reported, and identified an association with 
histopathological evidence of thrombotic microangiopathy, which is exceptionally rare as a spontaneous disease30 
(Supplementary Figure 1). Therefore thrombotic microangiopathy is observed in states of elevated endogenous and 
exogenous type I interferon in humans.  
 
Type I interferon signalling is species specific, limiting interpretation of preclinical toxicity tests 
Given this clinical evidence that TMA is a manifestation of interferon toxicity, we next sought to provide experimental 
evidence that the recombinant protein itself can cause the small vessel disease observed in the patients described 
here. To address whether interferon can directly cause microangiopathic disease in rodent models, we first evaluated 
available preclinical toxicity data used in the clinical development of both recombinant interferon -α and -β 
therapies31,32. No reports of microvascular toxicity were recorded in extensive preclinical testing of human recombinant 
protein in rodents. However, type I interferon signalling is highly species specific, and human interferon -α and -β do 
not cause upregulation of interferon response genes in mouse endothelial cells (Figure 3A,B). Therefore, preclinical 
rodent toxicity models cannot be used to evaluate whether interferon causes endothelial toxicity31,32.  
 
Transgenic overexpression of type I interferon causes a spectrum of microangiopathic disease, including 
changes seen in patient biopsies 
To overcome the problem of species disparity of interferon action, we utilised a species-matched transgenic mouse 
model to evaluate the effects of chronic type I interferon exposure on small blood vessels. In our model, type I 
interferon (IFNα1) is transgenically produced in the brain at zero (WT), low (IFNLow) or high (IFNHigh) levels, leading to 
focal graded activation of the interferon response via IFNAR (Figure 4A)16. Quantitative histopathological analyses 
identified a dose-dependent spectrum of microvascular disease, including endothelial hypertrophy and intimal 
thickening, microaneuryms and perivascular inflammatory infiltrates (Fig. 4C-F, Figure 5, Figure 6). This 
microangiopathy was observed across anatomical regions and was dose-dependent (Figure 4G, Figure 6D P<0.001 
one-way ANOVA).  
 
The three-dimensional morphology of small blood vessels are difficult to assess using conventional histopathological 
techniques, therefore we performed scanning electron microscope analysis of microvascular casts. This confirmed 
widespread microvascular abnormalities in the brain, with prominent variations in microvascular calibre including 
luminal stenosis and occlusions, ectasia and microaneurysms (Fig. 5, Figure 6K-M). These abnormalities were not 
seen in WT mice. This dose-dependent type I interferon-associated microangiopathy included pathological 
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microvascular abnormalities seen in the biopsies of the patients described above, such as endothelial hyperplasia, 
luminal occlusion and microaneursym formation (Figure 7A,B).  
 
To confirm this microvascular pathology is caused by activation of the interferon response through the type I interferon 
receptor IFNAR, we crossed IFNHigh mice with mice that were null for the type I interferon receptor 17, generating 
IFNHigh x IFNAR1-/- mice. Both upregulation of interferon response genes (IRG) and microvascular disease were 
absent in IFNHigh x IFNAR1-/- mice, confirming a critical role of IFNAR in mediating disease (Figure 7C,D). 
 
Taken together these data suggest that type I interferon therapies cause a dose-dependent thrombotic 
microangiopathy and the interferon protein itself can cause microangiopathic disease.  
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Discussion 
To date, unambiguous evidence of a causal association between type I interferon therapies and thrombotic 
microangiopathy has been lacking. This lack of evidence, together with a limited understanding of the serious adverse 
event, has hampered risk mitigation measures for these drugs and makes the clinical decision as to whether to stop 
interferon treatment in patients with TMA difficult. Thrombotic microangiopathy is a particularly challenging adverse 
drug event to study since it is rare and may occur after prolonged exposure to the drug. As such, randomised clinical 
trials are not powered to identify a causal association3,33. The detection of rare or delayed adverse events which occur 
outside trials typically relies on analysis of case reports and signal detection through spontaneous reporting data3. 
This approach is subject to bias and confounding and therefore even if an association is identified, a causal 
relationship cannot be inferred. A number of conceptual frameworks have been proposed when considering how to 
infer causality from observational clinical data10,34. Some of these frameworks, such as the well-known Bradford-Hill 
criteria10, suggest that experimental evidence can provide an important role in establishing causation by 
demonstrating biological plausibility, and direct evidence of causation in model systems. Our analyses of clinical, drug 
safety and experimental data satisfy the Bradford-Hill criteria and therefore support a causal link between type I 
interferon therapy and thrombotic microangiopathy (Supplementary Table 5).  
 
Careful definition of the adverse event of interest is central to the study of drug side-effects9. This is of particular 
relevance here since many cases of interferon-associated TMA have been reported using diverse terms including 
HUS7, TTP35 or malignant hypertension35,36, each implying a different pathophysiological process. It is therefore an 
important first step to define the clinical syndrome through a centre with expertise in the evaluation of this complex 
condition. Our analyses of cases suggest that interferon-β therapy is associated with a direct drug-induced thrombotic 
microangiopathy2. Direct drug-induced TMAs, such as those induced by VEGF inhibitors, are characterised by a 
gradual onset, exposure to high drug dose and absence of immunogenicity1,2,24. This phenotype is consistently 
reproduced in our cohort here. Three lines of evidence suggest that interferon-β associated TMA is associated with 
high dose therapy. Firstly, patients who developed the complication received nearly twice the weight-adjusted dose 
than patients who did not develop the complication. Secondly, our data shows that all cases of TMA spontaneously 
reported in the UK were associated with doses >50mcg/week. Thirdly, our experimental model recapitulates a striking 
dose-dependence of endothelial disease.  
  
While our primary focus here has been to address recent ongoing concerns regarding recombinant interferon-β use in 
multiple sclerosis patients, our wider analyses suggest that thrombotic microangiopathy is associated with all subtypes 
of recombinant type I interferon in clinical use. Comparison of case series evaluated at centres with TMA expertise 
suggests that TMA with interferon-α and interferon-β therapy display a similar clinical phenotype. In particular, both 
are associated with prolonged exposure to high doses of interferon, with chronic changes observed on biopsy. This is 
characterised by panendothelial disease with prominent renal, cerebral and cardiac involvement which may evolve 
over months. Further review of the published literature suggests that this clinical phenotype is consistently observed in 
almost all reported IFN-β TMA cases and most IFN-α TMA cases. Some patients with IFN-α TMA can occasionally 
present with a broader phenotype more suggestive of TTP, in particular patients with underlying haematological 
malignancies5. Future deep phenotypic study of this adverse event across centres will be important to determine the 
spectrum and true incidence of this disease, as well as the influence of underlying morbidity on clinical presentation. 
We propose that the most appropriate working descriptive term for this complication is “type I interferon-associated 
thrombotic microangiopathy”.  
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We have tested the hypothesis that type I interferon itself can directly cause microvascular disease. This hypothesis 
cannot be evaluated in preclinical rodent models due to the species-specificity of type I interferon signalling. We have 
therefore studied two complementary “species-matched” states of elevated type I interferon in mice and humans. 
Firstly, our mouse model here provides experimental advantage over preclinical rodent models, through species-
matching of interferon, and allows evaluation of the chronic effects of interferon exposure. Analysis of the 
microvasculature of this model demonstrates that type I interferon causes a spectrum of microangiopathy, with 
features that overlap with microvascular disease observed in the patients we describe. Secondly we show that TMA, 
which is exceptionally rare as a spontaneous disease30, is consistently observed across a broad spectrum of human 
“interferonopathic” diseases. In these disease states, interferon levels are spontaneously elevated in the context of 
activated innate immunity27. As such they might be considered by the Bradford-Hill criteria to represent an “analogous” 
system of human interferon toxicity. These diseases include rare genetic disorders of interferon dysregulation4,27,28, as 
well as more common autoimmune disorders such as SLE37. The precise subtypes of type I interferon which are 
elevated in these disease states are not yet fully described, but activation of the interferon response downstream of 
IFNAR is typically observed28. Microangiopathy is a major cause of organ damage in these patients (Supplementary 
Figure 1)38,39. For example, 25% of patients with SLE affecting the kidney have evidence of TMA on renal biopsy40,41 
and microangiopathy is a dominant brain pathology in patients with SLE 31. Therefore microangiopathic disease is 
consistently seen in mouse and human states of aberrantly elevated type I interferon. It is notable that in both patients 
and the mouse model we describe, microangiopathy is the dominant pathological feature, with microvascular 
thrombosis a less prominent feature. The lack of thrombosis on biopsy in many TMAs has resulted in a recent call for 
a change in nomenclature from TMA to microangiopathy with or without thrombosis to reflect this incongruity42. 
 
These findings are relevant to clinicians who must decide whether to stop recombinant type I interferon therapy in 
patients who develop thrombotic microangiopathy. Our data suggests a causal association and therefore the drug 
should be stopped at the earliest opportunity given the serious ensuing morbidity. Furthermore our findings are of 
relevance to risk mitigation strategies since they raise the possibility of stratification and monitoring. In particular 
detailed retrospective analysis of clinical features and biopsies of cases suggests that type I interferon causes a 
chronic TMA, which evolves over weeks to months, with a detectable prodrome (supplementary table 6). At present, 
renal function monitoring and blood pressure monitoring is not mandated for patients receiving type I interferon 
therapies and none of the patients described here were actively monitored for this complication. Therefore, despite a 
potential window of opportunity for early recognition, all patients presented at a late stage to emergency or critical care 
facilities. This late presentation is characterised by fulminant disease and organ failure, sometimes with fatal 
consequences.  
 
Additional blood pressure and renal function monitoring for TMA have subsequently been introduced across Scotland 
following concerns about the severity and incidence of this complication in multiple sclerosis patients, where an 
incidence of ~1:1000 patient-years has been observed in patients treated with high-dose interferon-β 6 (supplementary 
figure 2). This monitoring has led to prompt cessation of interferon-β in patients who have developed 
severe/accelerated hypertension associated with mild renal dysfunction. Since the implementation of targeted 
monitoring, no patients have developed fulminant organ failure due to interferon-associated TMA (supplementary 
Figure 2B). We suggest that further consideration should be given to risk mitigation measures for this serious adverse 
drug event.  
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In summary we have shown that type I interferon therapies cause a direct dose-dependent thrombotic 
microangiopathy and the interferon protein itself can directly damage small blood vessels. The chronic and dose-
dependent nature of this complication identifies an opportunity to reduce risk to the large numbers of patients exposed 
to these drugs. These findings should facilitate and stimulate definitive and rigorous pharmacoepidemiological study of 
this serious adverse event, with an emphasis on quantification of risk and the potential for mitigation across the 
available type I interferon therapies. In the meantime, clinicians should be aware of this association when assessing 
patients and stop recombinant type I interferon therapies at the earliest stage in patients who develop TMA. 
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Figure 1. Interferon-β causes a direct drug-induced thrombotic microangiopathy in multiple sclerosis patients. 
Recombinant interferon-β therapy causes a microangiopathy affecting multiple organs in multiple sclerosis (MS) 
patients: (A,B) MRI brain scan shows multiple small new lesions consistent with recent microvascular ischaemia, 
identified on diffusion-weighted sequences (white arrows). (C) Admission blood film showing fragmented red blood 
cells (black arrows). (D) Haematoxylin and Eosin stain of renal biopsy from patient shows pathological microvascular 
changes with endothelial swelling, luminal narrowing and trapped red blood cells (black arrow, scale bar = 25µm). (E) 
Patients who developed TMA, including patients from an independent cohort7, received a higher weight-adjusted dose 
than unaffected MS patients treated with the same interferon-β preparation, * P < 0.001 t-test (F) All UK reports of 
thrombotic microangiopathy associated with interferon-β are associated with IFNβ1a dose >50mcg/week and 92% 
associated with the highest available dose (n=15 reports) (G,H) Evidence of activation of interferon response in renal 
biopsy of affected patient (MxA immunohistochemistry, red, scale bar 10µm), with biopsy from patient with TMA not 
associated with interferon (G: genetic atypical HUS) for comparison.  
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Figure 2. Thrombotic microangiopathy is associated with all type I interferon subtypes in clinical use 
(A) An overview of type I interferon signalling. Interferon-α and interferon-β act via the transmembrane type I 
interferon receptor IFNAR, leading to widespread upregulation of interferon response genes. (3D protein models 
rendered using PyMOL Molecular Graphics System, Version 1.8.2.2 Schrödinger, LLC with protein data obtained from 
the Protein Data Bank43 www.rcsb.org) (B) Dendrogram of human recombinant interferon subtypes in clinical use. 
Recombinant type I interferon proteins associated with TMA highlighted in red (see supplementary figure 1 for full 
details). (C) Comparison of the transcriptomic response of human endothelial cells (HUVECs) to human interferon-α 
and interferon-β14. The transcriptional response of human endothelial cells to both type I interferon subtypes is highly 
correlated (r=0.97, genes with fold-change >1 shown).  
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Figure 3. Type I interferon signaling is species specific, limiting interpretation of cross-species preclinical 
toxicity models Type I interferon proteins (-α and -β) act through a common receptor (IFNAR), leading to activation 
of downstream interferon response genes (IRGs). (A) Preclinical toxicity testing of human recombinant type I 
interferon utilises cross-species testing. Human recombinant type I interferon does not elicit a downstream interferon 
response in mouse endothelial cells, as measured by quantitative PCR for type I interferon response genes in bEnd.5 
brain endothelial cell line. Despite extensive preclinical testing (355 mice tested with human interferon-α, 347 mice 
tested with human interferon-β), no reports of small vessel toxicity were observed in publically available preclinical 
tests for human recombinant type I interferon therapies tested in rodents31,32. (B) In contrast, dose-dependent 
upregulation of interferon response genes is observed in mouse endothelial cells exposed to same-species 
recombinant type I interferon in vitro (data represent mean +/-SEM * = P<0.05, t-test compared to no interferon, n=3 
experiments, IFN-α shown).  
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Figure 4. Type I interferon causes a dose-dependent microangiopathy 
(A) Overview of experimental design (see text), with structure of the fusion gene used to generate the GFAP-IFN-α 
transgenic mice. (B) Scanning electron micrograph of IFNHigh vascular cast, coloured to show larger vessels (red) and 
microvasculature (box, yellow) (C-E) Haematoxylin and eosin sections of mice with maximal interferon overexpression 
show a spectrum of dose-dependent microangiopathic pathology, including endothelial hypertrophy and intimal 
thickening (C), microaneurysms (black arrows, D) and perivascular inflammatory cell infiltration and red bloods cells 
within narrowed lumen (blue arrows, E). Scale bars = 20µm. (F) Scanning electron micrograph of small vessel cast 
showing variation in microvessel calibre (white arrows) (G) Microvascular pathology in interferon-overexpressing mice 
is dose-dependent, WT= wildtype, no transgenic overexpression, IFNLow = transgenic line with low interferon 
overexpression, IFNHigh = transgenic line with high interferon overexpression (n=8 mice per group. Data represent 
mean +/-SEM one-way ANOVA p<0.001). 
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Figure 5. Abnormal morphology of cerebral microvascular casts of IFNHigh mice demonstrated by scanning 
electron microscopy (A,B,C) Scanning electron micrograph of cerebral microvascular casts of wildtype mice at low 
(x25), medium (x80) and high power (x300). (D-F) Abnormal microvascular morphology in IFNHigh mice, with variations 
in microvessel calibre (red arrows), ectatic vessels and microaneurysms (blue arrows). Such microvascular 
abnormalities were observed in all IFNHigh mice with highest levels of brain-restricted interferon-α1 production (n=6) 
but not in wildtype mice.  
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Figure 6. Spectrum of microvascular abnormalities observed in a focal model of type I interferon toxicity.  
A spectrum of microvascular disease is observed in mice with transgenic production type I interferon in the brain, 
across all anatomical regions. (A-C) Dose-dependent microvascular pathology in the hippocampus of transgenic mice 
with zero, low and high levels of interferon overexpression. (Haematoxylin/eosin, abnormal small blood vessel 
highlighted by black arrow) (D) Dose-dependent microvascular pathology was observed across all major brain regions 
*** p<0.01 one-way ANOVA for each region n=8 each group. (E-G) Perivascular inflammatory cell infiltration: 
Haematoxylin/eosin (H+E), CD3 and CD31 immunohistochemistry shows small blood vessels with T-cell infiltration 
(CD3) and narrowing of lumen (CD31 endothelial marker). (H) Ectatic small vessel (I) Perivascular infiltration by T-
cells (CD3, brown). (J) intravascular calcification (Scale bars E-G=20µm, H,I = 40µm). Scanning electron microscopy 
of microvascular cast shows (K) multiple small capillary microaneurysms (L) large microaneurysm and (M) ectactic 
microvessel 
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Figure 7. Specific pathological features of interferon-associated microangiopathy are seen in patient renal 
biopsy material and are mediated through the type I interferon receptor (A-B) Microvascular pathology identified 
in this model includes specific pathological abnormalities such as luminal narrowing (black arrows), endothelial 
hyperplasia (green arrows) and microaneurysm formation (blue arrows), which were seen in the biopsies of the 
patients described above. Scale bars = 20µm. (C) Upregulation of interferon response genes (Isg15, Irf7, Cxcl10) was 
observed in IFNHigh transgenic mice and absent in mice which lack the type I interferon receptor (IFNHigh x IFNAR-/-). 
Total RNA was extracted from the brain of wildtype and transgenic mice and analyzed by ribonuclease protection 
assay and visualized by autoradiography (n=3 per group).  (D) Rescue of microvascular pathology in IFNHigh mice 
which lack the type I interferon receptor (IFNHigh x IFNAR-/-). Data represent mean +/-SEM *** P<0.001, t-test 
compared to IFNHigh n=8 regions. 
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Clinical Feature Number of cases 
n=8 
Underlying 
disease 
Relapsing remitting multiple sclerosis All 
Presenting 
features 
Microangiopathic haemolytic anaemia All 
Emergency/critical care admission All 
Severe/malignant hypertension All 
Renal Failure  All 
Additional organ involvement* All 
Specialist 
investigation 
Reduced ADAMTS13 activity*** None 
aHUS mutations** 
CFH, CFI, C3, CF, CD46, THBD 
None 
Immune reaction against IFN-β 
(neutralising antibody titre>20 NU/ml)*** 
None 
Chronicity Length of treatment > 5 years All 
Thrombotic microangiopathy with chronic changes on 
renal biopsy** 
All 
Dose dependence Treated with >50mcg/week All 
Weight in bottom quartile All 
Final Diagnostic 
Evaluation 
Direct drug-induced thrombotic microangiopathy All 
 
Table 1. Summary of clinical features of thrombotic microangiopathy associated with interferon-β referred to 
the national UK thrombotic microangiopathy centre. Summary of clinical features of new and index cases6 of 
interferon-associated thrombotic microangiopathy in multiple sclerosis patients referred to the national TMA centre in 
Newcastle. * neurological involvement 4/8 cases, cardiac involvement 6/8 cases **= data available for 7/8 cases. *** 
data available for 6/8 cases. Full clinical details of all cases are in Supplementary Table 1. Following diagnostic re-
evaluation the clinical phenotype of the cases was uniformly consistent with a direct drug-induced thrombotic 
microangiopathy2,24.   
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